Tagged with P

Korea Dr Jin San-Yoo, president and CEO of PharmAbcine, lifts the lid on the company’s combination therapy with MSD’s blockbuster oncology treatment Keytruda. Dr Yoo explains the rationale behind his decision to base his clinical trials in Australia and provides his assessment of the future for oncology drug development in the…

Rare Diseases Long regarded as a neglected backwater within the drug discovery landscape and the preserve of only a handful of niche players, the rare disease space has been undergoing an extraordinary turnaround in fortunes of late.   According to EvaluatePharma’s forecasts, orphan drug sales are set to grow 11 percent each…

Rare Diseases The 28th February 2019, marks the twelfth international Rare Disease Day. On and around this day hundreds of patient organisations from countries and regions across the globe will strive to raise awareness of some of the world’s rarest disease. For many of the rare diseases out there, we are yet to…

Ipsen Following on from Johnson & Johnson’s acquisition of Actelion in January 2017 and Takeda’s takeover of Shire two years later, pharma multinationals’ rush to snap up rare disease specialists continues with Ipsen’s proposed acquisition of Clementia Pharmaceuticals. Industry insiders predict that this trend is set to continue well into the…

Mexico Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). In this article, he introduces us to an exciting new youth program set up to improve unemployment rates in Mexico and how the pharmaceutical industry is getting involved.    The investment in human capital is an…

Japan Already established as one of the world’s leading markets for innovative and patented drugs, Japan is set to grow rapidly in 2019, partly as a result of a dramatic uptake in generics and biosimilars.   Japan’s pharmaceutical industry has long centred on strong innovation and patented drugs, but we are…

Opinion Despite the savings and increased patient access biosimilars have brought to health care systems across Europe, the US has been surprisingly slow in their adoption. Chip Davis, President and CEO, Association for Accessible Medicines breaks down the systematic challenges that must be addressed in order for the US biosimilars market to realize…

China The lowdown on what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Robert Hall of Ardent Search outlines what he looks for in potential candidates for country manager positions in China.   What are the qualities you look…

Spain Angeles Delgado, president of Spain and Portugal for Fujitsu, a globally leading Japanese ICT company, discusses the long history of the company’s presence in Spain and within its healthcare system. Delgado goes on to shed light on the affiliate’s ongoing projects in Spain and how Fujitsu is positioning itself as…

Egypt Dr Magdy Abdelhamid, president of the Egyptian Society of Cardiology, explains the main trends in cardiology in Egypt and the society’s prevention projects. He also gives insights into the latest technological programs being implemented in the country to ensure patient safety.   Smoking is a disaster in the country since…

Opinion For PharmaBoardroom, Ian Chamberlain has already covered the changing role of the medical rep and the line manager of tomorrow. This time he turns his attention to sales trainers and the skills they will need to expand on in coming years.   It is a myth that the longer I do…

Opinion Kelly du Plessis is CEO & Founder of Rare Diseases South Africa, a registered NPO born out of necessity when her oldest child was diagnosed with Pompe disease at 11 months old. Here she provides insights on where South Africa is at in terms of rare diseases and what needs…